Delivery Order SPE2DE24D0013-SPE2D625F2EYM
- Not listed
- The Defense Department's Medical Supply Chain awarded a $4,080 firm fixed-price delivery order to Cepheid Inc. on July 18, 2025, for molecular diagnostic solutions related to COVID-19, influenza, and respiratory syncytial virus (RSV) testing. The contract, designated as XPCOV2/FLU/RSV-10, represents a delivery order with an ultimate completion date of July 25, 2025, and carries no set-aside designation. Work will be performed at Cepheid's facility in Sunnyvale, California. This award reflects...
- The U.S. Defense Department's Medical Supply Chain awarded Cepheid Inc., a Sunnyvale, California-based molecular diagnostics manufacturer, a firm fixed-price delivery order valued at $20,400 on August 11, 2025, with an ultimate completion date of August 18, 2025. The delivery order, designated XPCOV2/FLU/RSV-10, involves diagnostic testing solutions for COVID-19, influenza, and respiratory syncytial virus (RSV)—infectious diseases commonly detected through Cepheid's GeneXpert molecular...
- The Defense Department's Medical Supply Chain division awarded a $3,400 firm fixed-price delivery order to Cepheid Inc. on July 30, 2025, for molecular diagnostic solutions related to COVID-19, influenza, and respiratory syncytial virus (RSV) testing. The contract, designated as delivery order XPCOV2/FLU/RSV-10, is scheduled for completion by August 6, 2025, and will be performed at Cepheid's facility in Sunnyvale, California. This award carries no set-aside designation and represents a...
- The U.S. Defense Department's Medical Supply Chain division awarded a $17,280 firm fixed-price delivery order to Cepheid Inc. on August 27, 2025, with an ultimate completion date of September 4, 2025. This delivery order, designated XPCOV2/FLU/RSV-10, procures molecular diagnostic solutions for detecting COVID-19, influenza, and respiratory syncytial virus. Cepheid, a Sunnyvale, California-based manufacturer of advanced diagnostic systems and test kits, was selected without a set-aside...
- The U.S. Defense Logistics Agency's Medical Supply Chain division awarded a $17,000 firm fixed-price delivery order to Cepheid Inc. (UEI: W6HQTMWB9Q28) on August 19, 2025, for molecular diagnostic solutions related to COVID-19, influenza, and respiratory syncytial virus testing. The contract, designated as XPCOV2/FLU/RSV-10, has an ultimate completion date of August 26, 2025, and will be performed at Cepheid's headquarters in Sunnyvale, California. No small business set-aside was utilized for...
- Cepheid Inc., a Sunnyvale, California-based manufacturer of molecular diagnostic solutions, was awarded a $3,400 firm fixed-price delivery order on July 28, 2025, for COVID-19, Influenza, and Respiratory Syncytial Virus (RSV) diagnostic testing supplies. The delivery order, contract number 4568910321, is set to be completed by August 4, 2025, and will be performed at Cepheid's Sunnyvale facility. The contract is funded by the Defense Department's Medical Supply Chain entity and utilizes no...
- Cepheid Inc., a Sunnyvale, California-based manufacturer of molecular diagnostic solutions, was awarded a delivery order valued at $3,400 by the Defense Logistics Agency (a component of the Department of Defense) on August 4, 2025, with a completion date of August 11, 2025. The delivery order, designated XPCOV2/FLU/RSV-10, involves firm fixed-price procurement of diagnostic testing solutions, specifically for COVID-19, influenza, and respiratory syncytial virus (RSV) detection capabilities. This...
- The Defense Logistics Agency's Medical Supply Chain division awarded a delivery order valued at $5,440 to Cepheid Inc. on August 25, 2025, for the supply of COVID-19, influenza, and respiratory syncytial virus (RSV) diagnostic solutions. This firm fixed-price delivery order, which is not set-aside designated, is scheduled for completion by September 2, 2025, and will be performed at Cepheid's facility in Sunnyvale, California. The award represents a continuation of Cepheid's established role...
- Cepheid Inc., a molecular diagnostic solutions manufacturer based in Sunnyvale, California, was awarded a firm fixed-price delivery order valued at $2,040 by the Defense Logistics Agency's Medical Supply Chain division on August 22, 2025. The delivery order, designated XPCOV2/FLU/RSV-10, is scheduled for completion by August 29, 2025, and covers molecular diagnostic testing solutions for detecting COVID-19, influenza, and respiratory syncytial virus (RSV). This award carries no set-aside...
- The U.S. Defense Department's Medical Supply Chain awarded a delivery order valued at $13,096.80 to Cepheid Inc. on July 28, 2025, for molecular diagnostic testing solutions. This firm fixed-price delivery order, designated 4568920464 and titled XPCOV2/FLU/RSV-10, carries an ultimate completion date of August 11, 2025, and will be performed at Cepheid's facility in Sunnyvale, California. The contract involves diagnostic testing capabilities for COVID-19, influenza, and respiratory syncytial...
- SPE2DE24D0013Indefinite Delivery Contract
- SPE2DE24D0013-SPE2D625F2EYMDelivery Order
The U.S. Defense Department's Medical Supply Chain organization awarded a $2,835 firm fixed-price delivery order to Cepheid Inc. on August 29, 2025, for molecular diagnostic testing solutions related to COVID-19, influenza, and respiratory syncytial virus (RSV) detection. The delivery order, which extends through September 8, 2025, will be performed at Cepheid's facility in Sunnyvale, California. This award carries no small business set-aside designation and represents a continuation of Cepheid's ongoing provision of diagnostic equipment and reagents to federal healthcare systems. This delivery order likely draws from one of Cepheid's two significant Indefinite Delivery/Indefinite Quantity (IDIQ) vehicles with the Department of Veterans Affairs, which collectively provide comprehensive molecular diagnostic testing capabilities across multiple federal agencies. Cepheid, a for-profit manufacturer specializing in advanced diagnostic systems and test kits for infectious diseases, has established itself as a key supplier of GeneXpert diagnostic systems and associated reagents to federal healthcare networks. The company's existing VA IDIQ contracts, valued at approximately $32.8 million and $2.5 million respectively, support ongoing procurement of molecular diagnostic solutions for conditions including COVID-19, influenza, RSV, and other infectious diseases, demonstrating the company's critical role in federal diagnostic infrastructure.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $2.8k | 8/29/25 |